Global specialty biopharmaceutical company Shire announces the appointment of Emmanuel Chantelot, former Executive Director of the European Biopharmaceutical Enterprises (EBE), as Director of European Government Relations and Public Policy.
Mr Chantelot will be responsible for further developing Shire’s relationships with the main European governmental institutions and building strategic partnerships with key stakeholders in Brussels. He will help foster understanding about Shire’s business with government and public policy stakeholders and influencers across Europe and forge partnerships on key healthcare issues. This senior appointment reflects Shire’s growing presence Internationally and follows the recent opening of a new European hub in Geneva, Switzerland. It also reflects Shire’s goal to develop stronger public/private sector partnerships in order to deliver better overall solutions to patients with specialist health needs.
Mr Chantelot brings 18 years of experience in policy advocacy, strategic communications and business interest representation towards the EU Institutions, global agencies and national governments.
“This is a new role reflecting a strong commitment to joining forces and participating with public sector stakeholders on behalf of patients. Emmanuel’s impressive background in EU government relations will help Shire carve out new styles of relationships that will ultimately enable better healthcare solutions to be delivered to patients.”, said Jessica Mann, Senior Vice President, Global Corporate Communications and Government Relations.
Mr Chantelot was previously Executive Director of European Biopharmaceutical Enterprises (EBE), a European trade association of 63 biopharmaceutical companies operating as the biotechnology arm of EFPIA, the European pharmaceutical industry federation. Before joining EBE in June 2006, he occupied senior management positions in global and European trade associations for different industry sectors and in an international management consultancy. A Belgian national, Mr Chantelot graduated with Masters Degrees in molecular biology and biotechnology from the Free University of Brussels and received management education at Northwestern University in Chicago.
For further information please contact:
|Media||Jessica Mann (firstname.lastname@example.org)||+44 1256 894 280|
Notes to editors
Shire is the 35th largest company in the FTSE100 with a market capitalization of £9.5 billion ($15 billion) as of 26 January 2011. Shire employs 4,100 people globally in 28 countries.
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.